Semaglutide Boosts Motivation and Effort in Major Depressive Disorder Patients

Individuals suffering from Major Depressive Disorder (MDD) often experience profound anhedonia, a reduced ability to experience pleasure or motivation, which significantly impairs daily functioning and is often resistant to conventional antidepressant treatments. While Semaglutide, a GLP-1 receptor agonist, is primarily known for its efficacy in type 2 diabetes and obesity, emerging research suggests its potential neuroprotective and anti-inflammatory properties. This study specifically addresses whether Semaglutide can improve effort-based decision-making, a key component of motivational deficits, in patients with MDD.

The trial demonstrated a significant improvement in effort-based decision-making among patients treated with Semaglutide. Participants in the Semaglutide group showed a 43% increase in high-effort choices on the EEfRT from baseline, compared to only a 12% increase in the placebo group (p<0.001). Anhedonia scores, as measured by the Snaith-Hamilton Pleasure Scale (SHAPS), decreased by an average of 3.8 points in the Semaglutide arm versus 1.1 points in the placebo group (p=0.003). The Semaglutide group exhibited a 2.7-fold greater improvement in overall motivational drive compared to the placebo group (p<0.001). Secondary analyses also indicated a 25% reduction in self-reported fatigue and a 15% improvement in overall mood scores in the active treatment group (p<0.05 for both), suggesting broader benefits beyond just effort-based decision-making.